Novel protein markers of androgen activity in humans: proteomic study of plasma from young chemically castrated men

Abstract

Background:

Reliable biomarkers of androgen activity in humans are lacking. The aim of this study was, therefore, to identify new protein markers of biological androgen activity and test their predictive value in relation to low vs. normal testosterone values and some androgen deficiency linked pathologies.

Methods:

Blood samples from 30 healthy GnRH-antagonist treated males were collected at three time points: a) before GnRH antagonist administration; b) 3 weeks later, just before testosterone undecanoate injection, and c) after additional 2 weeks. Subsequently they were analysed by mass spectrometry to identify potential protein biomarkers of testosterone activity. Levels of proteins most significantly associated with testosterone fluctuations were further tested in a cohort of 75 hypo- and eugonadal males suffering from infertility. Associations between levels of those markers and cardio-metabolic parameters, bone mineral density as well as androgen receptor CAG repeat lengths, were explored.

Results:

Using ROC analysis, 4-hydroxyphenylpyruvate dioxygenase (4HPPD), insulin-like growth factor-binding protein 6 (IGFBP6) and fructose-bisphosphate aldolase (ALDOB), as well as a Multi Marker Algorithm, based on levels of 4HPPD and IGFBP6, were shown to be best predictors of low (< 8 nmol/L) vs. normal (> 12 nmol/L) testosterone. They were also more strongly associated with metabolic syndrome and diabetes than testosterone levels. Levels of ALDOB and 4HPPD levels also showed association with AR CAG-repeat lengths.

Conclusions:

We identified potential new protein biomarkers of testosterone action. Further investigations to elucidate their clinical potential are warranted.

Funding:

The work was supported by ReproUnion 2.0 (grant no 20201846), which is funded by the Interreg V EU program.

Data availability

The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE (60) partner repository with the dataset identifier PXD024448.Supplementary tables (datasets):https://doi.org/10.6084/m9.figshare.14875431Source data of the Figures can be found on:https://doi.org/10.6084/m9.figshare.14875431Supplementary Figure S1 (Figure 2-figure supplement 1):https://doi.org/10.6084/m9.figshare.14876562

The following data sets were generated

Article and author information

Author details

  1. Aleksander Giwercman

    Department of Translational Medicine, Lund University, Malmo, Sweden
    For correspondence
    aleksander.giwercman@med.lu.se
    Competing interests
    Aleksander Giwercman, received consulting fees from Besins Healthcare. The author has no other competing interests to declare..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5816-0785
  2. K Barbara Sahlin

    Department of Biomedical Engineering, Lund University, Lund, Sweden
    Competing interests
    No competing interests declared.
  3. Indira Pla Parada

    Department of Biomedical Engineering, Lund University, Lund, Sweden
    Competing interests
    No competing interests declared.
  4. Krzysztof Pawlowski

    Department of Experimental Design and Bioinformatics, Warsaw University of Life Sciences, Warszawa, Poland
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5367-0935
  5. Carl Fehninger

    Department of Biomedical Engineering, Lund University, Lund, Sweden
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0922-7749
  6. Yvonne Lundberg Giwercman

    Department of Translational Medicine, Lund University, Malmo, Sweden
    Competing interests
    No competing interests declared.
  7. Irene Leijonhufvud

    Department of Translational Medicine, Lund University, Malmo, Sweden
    Competing interests
    No competing interests declared.
  8. Roger Appelqvist

    Department of Biomedical Engineering, Lund University, Lund, Sweden
    Competing interests
    No competing interests declared.
  9. György Marko-Varga

    Department of Biomedical Engineering, Lund University, Lund, Sweden
    Competing interests
    No competing interests declared.
  10. Aniel Sanchez

    Department of Biomedical Engineering, Lund University, Lund, Sweden
    Competing interests
    No competing interests declared.
  11. Johan Malm

    Department of Translational Medicine, Lund University, Malmo, Sweden
    Competing interests
    No competing interests declared.

Funding

ReproUnion (20201846)

  • Aleksander Giwercman

Swedish Governmental Fund for Clinical Research

  • Aleksander Giwercman

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: All subjects were enrolled with informed written consent. The two studies from which they were recruited were approved by the Swedish Ethical Review Authority (Approval number: DNR 2014/311, date of approval 8 May 2014; DNR 2011/1, date of approval 11 January 2011).

Copyright

© 2022, Giwercman et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 927
    views
  • 158
    downloads
  • 4
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Aleksander Giwercman
  2. K Barbara Sahlin
  3. Indira Pla Parada
  4. Krzysztof Pawlowski
  5. Carl Fehninger
  6. Yvonne Lundberg Giwercman
  7. Irene Leijonhufvud
  8. Roger Appelqvist
  9. György Marko-Varga
  10. Aniel Sanchez
  11. Johan Malm
(2022)
Novel protein markers of androgen activity in humans: proteomic study of plasma from young chemically castrated men
eLife 11:e74638.
https://doi.org/10.7554/eLife.74638

Share this article

https://doi.org/10.7554/eLife.74638

Further reading

    1. Medicine
    2. Neuroscience
    Jie Zhang, Jianguo Cheng
    Insight

    A complex extracted from the amniotic membrane in humans reduces post-surgical pain in mice by directly inhibiting pain-sensing neurons.

    1. Medicine
    2. Neuroscience
    Jörn Lötsch, Khayal Gasimli ... Marco Sisignano
    Research Article

    Background:

    Chemotherapy-induced peripheral neuropathy (CIPN) is a serious therapy-limiting side effect of commonly used anticancer drugs. Previous studies suggest that lipids may play a role in CIPN. Therefore, the present study aimed to identify the particular types of lipids that are regulated as a consequence of paclitaxel administration and may be associated with the occurrence of post-therapeutic neuropathy.

    Methods:

    High-resolution mass spectrometry lipidomics was applied to quantify d=255 different lipid mediators in the blood of n=31 patients drawn before and after paclitaxel therapy for breast cancer treatment. A variety of supervised statistical and machine-learning methods was applied to identify lipids that were regulated during paclitaxel therapy or differed among patients with and without post-therapeutic neuropathy.

    Results:

    Twenty-seven lipids were identified that carried relevant information to train machine learning algorithms to identify, in new cases, whether a blood sample was drawn before or after paclitaxel therapy with a median balanced accuracy of up to 90%. One of the top hits, sphinganine-1-phosphate (SA1P), was found to induce calcium transients in sensory neurons via the transient receptor potential vanilloid 1 (TRPV1) channel and sphingosine-1-phosphate receptors.SA1P also showed different blood concentrations between patients with and without neuropathy.

    Conclusions:

    Present findings suggest a role for sphinganine-1-phosphate in paclitaxel-induced biological changes associated with neuropathic side effects. The identified SA1P, through its receptors, may provide a potential drug target for co-therapy with paclitaxel to reduce one of its major and therapy-limiting side effects.

    Funding:

    This work was supported by the Deutsche Forschungsgemeinschaft (German Research Foundation, DFG, Grants SFB1039 A09 and Z01) and by the Fraunhofer Foundation Project: Neuropathic Pain as well as the Fraunhofer Cluster of Excellence for Immune-Mediated Diseases (CIMD). This work was also supported by the Leistungszentrum Innovative Therapeutics (TheraNova) funded by the Fraunhofer Society and the Hessian Ministry of Science and Arts. Jörn Lötsch was supported by the Deutsche Forschungsgemeinschaft (DFG LO 612/16-1).